The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress
Platinum chemotherapies are highly effective cytotoxic agents but often induce resistance when used as monotherapies. Combinatorial strategies limit this risk and provide effective treatment options for many cancers. Here, we repurpose atovaquone (ATQ), a well-tolerated & FDA-approved anti-malar...
Автори: | Coates, JTT, Rodriguez-Berriguete, G, Puliyadi, R, Ashton, T, Prevo, R, Wing, A, Granata, G, Pirovano, G, McKenna, GW, Higgins, GS |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Springer Nature
2020
|
Предмети: |
Схожі ресурси
Схожі ресурси
-
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
за авторством: Ashton, T, та інші
Опубліковано: (2016) -
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
за авторством: Thomas M. Ashton, та інші
Опубліковано: (2016-07-01) -
CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner
за авторством: Prevo, R, та інші
Опубліковано: (2018) -
Investigating the role of the anti-malarial drug Atovaquone in anti-cancer therapy
за авторством: Watson, D, та інші
Опубліковано: (2019) -
Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models
за авторством: Gonzalo Rodriguez-Berriguete, та інші
Опубліковано: (2024-01-01)